Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Altimmune, Inc. (ALT)

Altimmune Appoints Two Directors, Expanding Board to Eleven Members

Neutral Impact 3 of 5 leadership Written later

Altimmune said its board appointed Peter Greenleaf and Alex Howarth as directors effective November 2, 2026, increasing the board from nine to eleven seats. Three current directors, John Gill, Mitchel Sayare and Klaus Schafer, will retire at the 2027 annual meeting rather than stand for re-election, and the company said their departures are not due to any disagreement with the company.

Key points

  • Peter Greenleaf (54), former CEO of Aurinia Pharmaceuticals, and Alex Howarth (58), former CFO of Madrigal Pharmaceuticals, join the board effective November 2, 2026.
  • Board size increases from nine to eleven directors.
  • Gill, Sayare and Schafer continue as directors until the 2027 Annual Meeting, then retire.
  • Each new director receives an initial stock option award for 160,000 shares and a $40,000 annual cash retainer.

The filing

CompanyAltimmune, Inc. (ALT)
Form8-K, current report
Filed with the SECOct 27, 2026, 8:16 AM ET
Accession number0001104659-26-118991

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.